Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia

Abstract Background Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 ge...

Full description

Bibliographic Details
Main Authors: Wijden Mahfoudh, Inchirah Bettaieb, Randa Ghedira, Kaouther Snoussi, Nadia Bouzid, Zahra Klayech, Sallouha Gabbouj, Yassmine Remadi, Elham Hassen, Noureddine Bouaouina, Abdelfateh Zakhama
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Journal of Translational Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12967-019-1873-8
_version_ 1819037485896826880
author Wijden Mahfoudh
Inchirah Bettaieb
Randa Ghedira
Kaouther Snoussi
Nadia Bouzid
Zahra Klayech
Sallouha Gabbouj
Yassmine Remadi
Elham Hassen
Noureddine Bouaouina
Abdelfateh Zakhama
author_facet Wijden Mahfoudh
Inchirah Bettaieb
Randa Ghedira
Kaouther Snoussi
Nadia Bouzid
Zahra Klayech
Sallouha Gabbouj
Yassmine Remadi
Elham Hassen
Noureddine Bouaouina
Abdelfateh Zakhama
author_sort Wijden Mahfoudh
collection DOAJ
description Abstract Background Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. However, the contribution and the frequency of BRCA1 mutations in individuals with TNBC, not specifically selected for age at diagnosis or enriched family history of breast/ovarian cancer, have not been investigated in the Tunisian population and are to be established. The aim of the present study was to assess the contribution and the prevalence of recurrent BRCA1 germline mutation (5382inC) in Tunisian women with TNBC unselected for family history or age at onset. Methods For BRCA1 5382inC mutation detection, the exon 20 coding region and exon–intron boundaries of BRCA1 was analyzed using direct DNA sequencing. A total of 33 DNA samples from Tunisian women diagnosed with TNBC and unselected for family history or age at onset were analyzed. Results The 5382inC mutation was identified in 2 out of 33 women with TNBC with an overall prevalence of 6% (2/33). The detection rate of the 5382inC mutation among TNBC women with family history of breast cancer was 25% (2/8). The two 5382inC mutation carriers were postmenopausal and diagnosed at the age of 50 and 57. When stratified by age, the frequency of BRCA1 mutation in patients diagnosed at age ≥ 50 years was 8.7% (2/23). Conclusions Our results confirm a noticeable contribution of BRCA1 5382inC mutation in TNBC development in Tunisia and further indicate that screening for 5382insC mutation in the BRCA1 gene is of interest in genetic testing in our population. Additionally, our data highlight that receptor triple negativity could be an effective selection criterion for BRCA1 genetic test in our population and should therefore be considered in genetic testing guidelines in Tunisia.
first_indexed 2024-12-21T08:22:10Z
format Article
id doaj.art-f0a71baad6d24480b824ff054410db7d
institution Directory Open Access Journal
issn 1479-5876
language English
last_indexed 2024-12-21T08:22:10Z
publishDate 2019-04-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj.art-f0a71baad6d24480b824ff054410db7d2022-12-21T19:10:25ZengBMCJournal of Translational Medicine1479-58762019-04-011711510.1186/s12967-019-1873-8Contribution of BRCA1 5382insC mutation in triple negative breast cancer in TunisiaWijden Mahfoudh0Inchirah Bettaieb1Randa Ghedira2Kaouther Snoussi3Nadia Bouzid4Zahra Klayech5Sallouha Gabbouj6Yassmine Remadi7Elham Hassen8Noureddine Bouaouina9Abdelfateh Zakhama10Laboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityHigher Institute of Biotechnology of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityLaboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir UniversityAbstract Background Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. However, the contribution and the frequency of BRCA1 mutations in individuals with TNBC, not specifically selected for age at diagnosis or enriched family history of breast/ovarian cancer, have not been investigated in the Tunisian population and are to be established. The aim of the present study was to assess the contribution and the prevalence of recurrent BRCA1 germline mutation (5382inC) in Tunisian women with TNBC unselected for family history or age at onset. Methods For BRCA1 5382inC mutation detection, the exon 20 coding region and exon–intron boundaries of BRCA1 was analyzed using direct DNA sequencing. A total of 33 DNA samples from Tunisian women diagnosed with TNBC and unselected for family history or age at onset were analyzed. Results The 5382inC mutation was identified in 2 out of 33 women with TNBC with an overall prevalence of 6% (2/33). The detection rate of the 5382inC mutation among TNBC women with family history of breast cancer was 25% (2/8). The two 5382inC mutation carriers were postmenopausal and diagnosed at the age of 50 and 57. When stratified by age, the frequency of BRCA1 mutation in patients diagnosed at age ≥ 50 years was 8.7% (2/23). Conclusions Our results confirm a noticeable contribution of BRCA1 5382inC mutation in TNBC development in Tunisia and further indicate that screening for 5382insC mutation in the BRCA1 gene is of interest in genetic testing in our population. Additionally, our data highlight that receptor triple negativity could be an effective selection criterion for BRCA1 genetic test in our population and should therefore be considered in genetic testing guidelines in Tunisia.http://link.springer.com/article/10.1186/s12967-019-1873-8Triple negative breast cancer (TNBC)BRCA15382inC mutationTunisia
spellingShingle Wijden Mahfoudh
Inchirah Bettaieb
Randa Ghedira
Kaouther Snoussi
Nadia Bouzid
Zahra Klayech
Sallouha Gabbouj
Yassmine Remadi
Elham Hassen
Noureddine Bouaouina
Abdelfateh Zakhama
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
Journal of Translational Medicine
Triple negative breast cancer (TNBC)
BRCA1
5382inC mutation
Tunisia
title Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_full Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_fullStr Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_full_unstemmed Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_short Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_sort contribution of brca1 5382insc mutation in triple negative breast cancer in tunisia
topic Triple negative breast cancer (TNBC)
BRCA1
5382inC mutation
Tunisia
url http://link.springer.com/article/10.1186/s12967-019-1873-8
work_keys_str_mv AT wijdenmahfoudh contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT inchirahbettaieb contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT randaghedira contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT kaouthersnoussi contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT nadiabouzid contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT zahraklayech contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT sallouhagabbouj contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT yassmineremadi contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT elhamhassen contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT noureddinebouaouina contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT abdelfatehzakhama contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia